12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Company News  |  Deals

InterMune, Vidara Therapeutics deal

InterMune will divest to Vidara worldwide rights to develop and commercialize Actimmune interferon (IFN) gamma-1b for $55 million in cash. InterMune is also eligible for tiered royalties for two years, which the company said could add about 5% to the purchase price. InterMune...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >